口服抗凝药物和中枢神经系统相关的血液瘤:来自FAERS数据库的药监测分析
1Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, 450003, China.
European journal of pharmacology
|September 18, 2025
概括
口服抗凝剂 (OAC) 治疗与中枢神经系统 (CNS) 血液瘤不良事件 (hAEs) 有关. 华法林显示的风险最高,而晚年和低体重增加了这些早期发病事件的死亡风险.
科学领域:
- 药物监督 药物监督 药物监督
- 神经学 神经学
- 心脏病学 心脏病学
背景情况:
- 中枢神经系统 (CNS) 血瘤不良事件 (hAEs) 是口服抗凝剂 (OAC) 治疗患者的严重并发症.
- 了解不同OAC对中枢神经系统-hAEs的比较风险对于患者安全至关重要.
研究的目的:
- 在各种OAC中分析和描述与中枢神经系统相关的HAE风险.
- 确定中枢神经系统-hAEs的死亡率和时间模式的风险因素.
主要方法:
- 来自美国食品和药物管理局不良事件报告系统 (FAERS) 数据库的中枢神经系统hAEs的分析.
- 不成比例分析 (报告赔率比率) 以确定OAC特定的信号.
- 对于死亡风险因素的后勤回归和时间模式的时间到发病分析.
主要成果:
- 所有OAC都显示了中枢神经系统hAEs的积极信号,华法林具有最高的关联 (ROR=38.31).
- 腹腔内血瘤是最常见的类型 (74.0%).
- 独立的死亡预测因素包括晚年 (≥75岁),低体重 (<60公斤),多次不良事件和抗抑郁药的使用. 与NOAC (158.5-228.0天) 相比,华法林的中位发病时间更长 (435.5天).
结论:
- OAC与中枢神经系统-hAEs有关,其中的风险在代理人之间有所不同.
- 高龄,低体重,多种副作用和抗抑郁药的使用是死亡的关键风险因素.
- 中枢神经系统hAEs通常发生在治疗的早期,需要优化风险管理策略.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Venous Thrombosis IV: Nursing Management
202
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
202


